Bank of America Merrill Lynch downgraded AGCO Corporation (NYSE: AGCO) on data suggesting the global tractor market recovery is not materializing.
The firm downgraded AGCO from Neutral to Underperform and lowered its price target for the company from $75 to $70.
At the time of writing, the farm equipment company's shares were sliding 2.75 percent to $72.60.
Weakness All Around
While AGCO expected flat Brazilian demand in the second half of 2017 following a sharp recovery in the first half, analyst Ross Gilardi said Brazilian tractor sales instead fell in the third quarter.
Recent tractor data from Europe, which accounts for 80 percent of AGCO's EBIT, is incrementally weaker, Gilardi said. (See Gilardi's track record here.)
North America didn't fare any better, with a 14 percent decline in HHP tractor sales in September on top of a 2 percent drop in August.
BofA lowered its 2018-19 EPS estimate for AGCO by 3-4 percent on the weak tractor data.
While the global tractor market data remained negative, Gilardi said AGCO stock was trading at an all-time high, discounting a sustained farm equipment recovery.
With the stock having hit BofA's previous price objective of $75, the analyst said he doesn't project it will push higher.
CNH Industrial NV (NYSE: CNHI) and Deere, though impacted by weak agricultural equipment data, are more diversified, with Buy-rated CNH Industrial remaining a compelling break-ups tory, Gilardi said.
Deere is expected to close soon on the highly accretive Wirtgen acquisition, which is yet to be reflected in consensus estimates, the analyst said.
Will Ag Stocks Flourish Now That California's 5-Year Drought Is Officially Over?
2 Ag Names Win Bank Of America Upgrades
Latest Ratings for AGCO
|Oct 2017||Bank of America||Downgrades||Neutral||Underperform|
|Oct 2017||JP Morgan||Downgrades||Neutral||Underweight|
|Aug 2017||BMO Capital||Maintains||Market Perform|
View More Analyst Ratings for AGCO
View the Latest Analyst Ratings
See more from Benzinga
- Why The Market Isn't Giving Citigroup Credit For Its Q3 Beat
- Bank Of America Sees NewLink Genetics As 'Undervalued'
- First Impression Of JPMorgan's 'Solid' Q3
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.